What Makes Eli Lilly And Co. (LLY) a Worthy Holding?

Core Insights - Alpha Wealth Insiders Fund reported a return of 4.96% in September 2025, with year-to-date returns reaching 21.37%, outperforming the S&P 500's September return of 3.65% and year-to-date return of 14.83% [1] Group 1: Company Performance - Eli Lilly and Company (NYSE: LLY) achieved a one-month return of 5.93% and a 52-week gain of 38.12%, closing at $1,074.68 per share with a market capitalization of $963.404 billion on December 31, 2025 [2] - Eli Lilly's revenue grew by 54% in Q3 2025 compared to the same period last year, indicating strong business performance [4] Group 2: Business Overview - Eli Lilly is recognized as a pharmaceutical powerhouse, known for its products like Mounjaro and Zepbound in weight-loss and diabetes treatment, as well as its cancer and immunology drugs, and a promising Alzheimer's pipeline [3] - The company's stock is benefiting from the GLP-1 wave, contributing to significant growth and market-cap dominance [3] Group 3: Market Position - Eli Lilly ranks 21st among the 30 most popular stocks among hedge funds, with 114 hedge fund portfolios holding its stock at the end of Q3 2025, a slight decrease from 119 in the previous quarter [4]